The answer to one of modern medicine’s more surprising stories starts with a genetic quirk. People born with familial renal glycosuria, a rare inherited kidney condition caused by mutations in the SLC5A2 gene, constantly spill glucose into their urine — yet they live completely normal, healthy lives. That observation, combined with research stretching back to a compound found in apple tree bark in 1835, led scientists to develop SGLT2 inhibitors: a class of drugs that deliberately mimics this rare condition to lower blood sugar in people with type 2 diabetes. Today, medications like dapagliflozin (Farxiga), empagliflozin (Jardiance), and canagliflozin (Invokana) represent a global market estimated at $13 to $21 billion in 2025 and are reshaping treatment not just for diabetes, but for heart failure and chronic kidney disease as well. For readers of this site, the relevance is not abstract.
Diabetes and cardiovascular disease are among the most significant modifiable risk factors for dementia and cognitive decline. Chronic kidney disease, too, has been linked to accelerated brain aging. Any drug class that meaningfully reduces the burden of these conditions has downstream implications for brain health — even if that was never part of the original plan. This article traces the unlikely journey from a rare kidney condition to a blockbuster drug class, explains how SGLT2 inhibitors work and where they fall short, and examines what the expanding reach of these medications might mean for people concerned about long-term cognitive health. The story also touches on the broader 2025 landscape in nephrology, including six new kidney disease medications approved by the FDA, and how these advances fit into the larger picture of protecting both body and brain as we age.
Table of Contents
- How Did a Rare Kidney Condition Lead to a Drug That Treats Diabetes?
- Which SGLT2 Inhibitors Are Approved and What Do They Actually Do?
- Beyond Diabetes — How SGLT2 Inhibitors Became Heart and Kidney Drugs
- What Does This Mean for Brain Health and Dementia Risk?
- Limitations, Side Effects, and Who Should Be Cautious
- The 2025 Nephrology Landscape and New Treatment Options
- What Comes Next for SGLT2 Inhibitors and Brain Health Research
- Conclusion
- Frequently Asked Questions
How Did a Rare Kidney Condition Lead to a Drug That Treats Diabetes?
Familial renal glycosuria is not a disease most doctors ever encounter. It affects a small number of people worldwide and results from a loss-of-function mutation in the gene encoding the SGLT2 protein — a transporter in the kidneys responsible for reabsorbing glucose back into the bloodstream. In people with FRG, glucose passes straight through the kidneys and into the urine. What made this condition so important to pharmaceutical research was not its rarity but its benignity: people with FRG do not develop low blood sugar, they do not suffer kidney damage, and they do not appear to face any serious long-term health consequences. That was the proof of concept. If nature could shut down SGLT2 safely, perhaps a drug could do the same thing on purpose. The intellectual thread connecting FRG to modern diabetes drugs runs through phlorizin, a compound isolated from apple tree root bark by French chemists in 1835. In the 1880s, German physician Josef von Mering discovered that phlorizin caused animals to excrete glucose in their urine.
By 1933, scientists had confirmed the same effect in humans and observed that it lowered blood glucose levels. But phlorizin was a blunt instrument — it inhibited both SGLT1 and SGLT2, caused intestinal side effects because SGLT1 operates in the gut, and was poorly absorbed when taken orally. It took decades of additional work before researchers could create a selective drug. In 1995, NIDDK-funded researchers confirmed phlorizin’s dual inhibition of SGLT1 and SGLT2, and that finding kicked off the focused effort to develop selective SGLT2-only inhibitors that would spare the gut and be practical as oral medications. The comparison to how most diabetes drugs were developed is stark. Insulin, metformin, sulfonylureas — these all emerged from studying the pancreas, the liver, or glucose metabolism directly. SGLT2 inhibitors came from studying the kidney and, more specifically, from studying people whose kidneys worked differently from birth. It was a lateral move, and one that took over 150 years from the isolation of phlorizin to the first FDA approval.
Which SGLT2 Inhibitors Are Approved and What Do They Actually Do?
The first SGLT2 inhibitor to reach the U.S. market was canagliflozin (Invokana), approved by the FDA in March 2013. Dapagliflozin (Farxiga) followed in January 2014, and empagliflozin (Jardiance) in August 2014. Ertugliflozin (Steglatro) was later approved for type 2 diabetes, and sotagliflozin received approval for heart failure. All three of the major SGLT2 inhibitors — canagliflozin, dapagliflozin, and empagliflozin — are now also approved for pediatric patients aged 10 and older, a notable expansion given how few diabetes drug classes have pediatric indications. These drugs work by blocking the SGLT2 transporter in the kidneys, preventing glucose reabsorption and causing excess glucose to be excreted in urine.
The mechanism lowers blood sugar without relying on insulin secretion or sensitivity, which means it carries a low risk of hypoglycemia — one of the most feared complications of older diabetes medications. Patients also tend to lose modest amounts of weight and see reductions in blood pressure, both of which are useful in a population that frequently struggles with obesity and hypertension. However, the mechanism is not without trade-offs. Because glucose in the urine creates a favorable environment for bacteria and yeast, genital mycotic infections (fungal infections) are a well-documented side effect, particularly in women. There is also a rare but serious risk of diabetic ketoacidosis, sometimes occurring even when blood sugar levels appear near-normal — a phenomenon called euglycemic DKA that can catch both patients and clinicians off guard. If you are someone managing type 2 diabetes and considering these medications, the practical point is this: SGLT2 inhibitors are not a substitute for foundational lifestyle measures, and they are not risk-free. But they offer a genuinely different mechanism of action from other drug classes, and for many patients, they provide benefits that extend well beyond glucose control.
Beyond Diabetes — How SGLT2 Inhibitors Became Heart and Kidney Drugs
What transformed SGLT2 inhibitors from useful diabetes medications into one of the most talked-about drug classes in medicine was a series of landmark clinical trials that showed benefits far beyond blood sugar. The CREDENCE trial demonstrated that canagliflozin significantly reduced the risk of end-stage kidney disease and cardiovascular death in people with type 2 diabetes and chronic kidney disease. The DAPA-CKD trial showed that dapagliflozin slowed kidney disease progression even in patients who did not have diabetes at all. The EMPA-KIDNEY trial confirmed similar results for empagliflozin. Across all three trials, the pattern was consistent: significant reductions in sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization.
These results led to regulatory approvals that fundamentally changed who these drugs are for. Dapagliflozin and empagliflozin are now approved for heart failure and chronic kidney disease regardless of whether the patient has diabetes. The 2024 KDIGO guidelines — the international standard for kidney disease management — now strongly recommend SGLT2 inhibitors to slow CKD progression in adults with an eGFR of 20 mL/min/1.73 m² or above, again regardless of diabetes status. In March 2026, NICE updated UK guidelines to include SGLT2 inhibitors as first-line treatment for type 2 diabetes, reflecting the accumulated weight of evidence for their cardiovascular and renal benefits. For a concrete example: a 62-year-old woman with early-stage chronic kidney disease and no diabetes diagnosis might now be prescribed dapagliflozin specifically to protect her kidneys, a scenario that would have been unthinkable a decade ago. The global SGLT2 inhibitor market is growing at a compound annual growth rate of 6 to 7 percent through 2034 and beyond, driven largely by these expanding non-diabetes indications.
What Does This Mean for Brain Health and Dementia Risk?
This is where the story becomes directly relevant to anyone reading a dementia care and brain health site. Type 2 diabetes roughly doubles the risk of Alzheimer’s disease and vascular dementia. Chronic kidney disease is independently associated with cognitive decline, likely through vascular damage, inflammation, and the accumulation of uremic toxins that cross the blood-brain barrier. Heart failure reduces cardiac output to the brain and has been linked to accelerated cognitive aging. Any drug that meaningfully addresses all three of these conditions has at least theoretical potential to protect cognitive function over the long term, even if it was never designed with the brain in mind. The direct evidence for SGLT2 inhibitors and dementia prevention is still emerging.
Observational studies and post-hoc analyses of the major trials have suggested possible neuroprotective effects, but no large randomized controlled trial has been designed specifically to test whether these drugs prevent or slow dementia. That is an important caveat. The biological plausibility is strong — reducing hyperglycemia, lowering blood pressure, protecting kidney function, and reducing heart failure hospitalizations all address known contributors to brain vascular damage — but plausibility is not proof. The practical takeaway is not that anyone should take an SGLT2 inhibitor specifically for brain health. It is that if you or a family member is already managing diabetes, kidney disease, or heart failure, and an SGLT2 inhibitor is part of the treatment plan, there may be an additional — if not yet fully proven — layer of cognitive protection built into that choice. Conversely, if these conditions are being undertreated or unmanaged, the downstream risks to the brain compound over time.
Limitations, Side Effects, and Who Should Be Cautious
SGLT2 inhibitors are not appropriate for everyone, and the enthusiasm surrounding their expanded indications should not obscure their real limitations. Genital fungal infections remain the most common side effect and are a genuine quality-of-life concern for some patients. Urinary tract infections occur at modestly elevated rates. The risk of euglycemic diabetic ketoacidosis, while rare, is particularly dangerous because it can present without the high blood sugar readings that typically trigger alarm — meaning patients and even emergency departments may not recognize it quickly. There are also population-specific concerns. Patients with very low kidney function (eGFR below 20) may not benefit and are generally outside the recommended range.
People with type 1 diabetes are not candidates for most SGLT2 inhibitors due to the heightened ketoacidosis risk. Older adults with low blood pressure or those on diuretics may experience dehydration or hypotension, since these drugs increase urine output. Canagliflozin, specifically, carried an early signal for increased amputation risk in the CANVAS trial, though subsequent data and real-world evidence have been more reassuring on that front. The broader lesson is that SGLT2 inhibitors are powerful tools, not panaceas. Their benefits in heart failure and CKD are robust, but they must be prescribed and monitored within the context of each individual’s full medical picture. For caregivers managing a loved one’s complex medication regimen — which is common in the dementia care space — awareness of these side effects and the need for adequate hydration is important practical knowledge.
The 2025 Nephrology Landscape and New Treatment Options
The expansion of SGLT2 inhibitors into kidney and heart disease was part of a broader wave. In January 2025, the FDA expanded Ozempic (semaglutide) approval to include kidney protection for adults with type 2 diabetes and chronic kidney disease — the first GLP-1 receptor agonist to receive such an indication. In November 2025, phase 3 trial results published in the New England Journal of Medicine showed that finerenone (Kerendia), a nonsteroidal mineralocorticoid receptor antagonist, was effective for type 1 diabetes patients with CKD.
Overall, 2025 was characterized as a landmark year for nephrology, with six new kidney disease medications approved by the FDA. For patients and families navigating the dementia care landscape, this matters because kidney disease and its treatments have direct effects on drug metabolism, toxin clearance, and vascular health — all of which influence brain function. The availability of multiple effective kidney-protective therapies means that CKD, once a condition managed primarily through dialysis and blood pressure control, now has a much deeper pharmacological toolkit. Better kidney health over a lifetime translates, at least in part, to better brain health.
What Comes Next for SGLT2 Inhibitors and Brain Health Research
The trajectory of SGLT2 inhibitors suggests that their story is far from over. Researchers are investigating potential benefits in conditions ranging from liver disease to gout to polycystic kidney disease. The most intriguing frontier for readers of this site is whether dedicated clinical trials will eventually test these drugs as a dementia prevention strategy in high-risk populations — for example, people with both type 2 diabetes and mild cognitive impairment.
The global SGLT2 inhibitor market, estimated between $13 and $21 billion in 2025 and growing at 6 to 7 percent annually, creates substantial financial incentive for manufacturers to pursue new indications. Whether neuroprotection will be among them depends on the willingness of researchers and funders to design the right trials. In the meantime, the story of SGLT2 inhibitors remains one of the more remarkable examples of how studying rare, seemingly inconsequential genetic conditions can lead to treatments that benefit millions — and possibly, in ways we are only beginning to understand, protect the aging brain as well.
Conclusion
The journey from familial renal glycosuria — a rare, harmless kidney quirk — to a multi-billion-dollar class of drugs that treats diabetes, heart failure, and chronic kidney disease is one of modern medicine’s most instructive stories. SGLT2 inhibitors like dapagliflozin, empagliflozin, and canagliflozin have demonstrated, through rigorous clinical trials, that mimicking a natural genetic variant can yield broad therapeutic benefits. For the dementia care community, these drugs matter because they address three of the most significant modifiable risk factors for cognitive decline: uncontrolled blood sugar, kidney disease, and heart failure.
If you or someone you care for lives with any of these conditions, a conversation with their physician about whether an SGLT2 inhibitor is appropriate is worth having. These are not miracle drugs, and they come with real side effects that require monitoring. But the evidence base is deep, the indications are expanding, and the potential for downstream brain health benefits adds another reason to ensure that diabetes, kidney disease, and heart failure are managed as aggressively as possible. Protecting the brain, in many cases, starts with protecting the heart and kidneys.
Frequently Asked Questions
What is familial renal glycosuria and why is it important?
Familial renal glycosuria (FRG) is a rare inherited condition caused by mutations in the SLC5A2 gene that result in persistent glucose excretion in urine despite normal blood sugar levels. People with FRG live completely normal, healthy lives. Its importance lies in providing proof-of-concept that blocking the SGLT2 transporter is safe long-term and does not cause hypoglycemia, which gave researchers the confidence to develop SGLT2 inhibitor drugs.
Can SGLT2 inhibitors prevent dementia or cognitive decline?
There is no definitive proof yet. No large randomized controlled trial has specifically tested whether SGLT2 inhibitors prevent or slow dementia. However, the biological plausibility is strong because these drugs address diabetes, heart failure, and kidney disease — all established risk factors for cognitive decline. Observational data is suggestive but not conclusive.
Are SGLT2 inhibitors only for people with diabetes?
No. Dapagliflozin and empagliflozin are now approved for heart failure and chronic kidney disease regardless of whether the patient has diabetes. The 2024 KDIGO guidelines strongly recommend them for adults with CKD and an eGFR of 20 mL/min/1.73 m² or above, irrespective of diabetes status.
What are the most common side effects of SGLT2 inhibitors?
The most common side effects are genital fungal infections and, to a lesser extent, urinary tract infections. A rare but serious risk is euglycemic diabetic ketoacidosis, which can occur even when blood sugar levels appear near-normal. Dehydration and low blood pressure can also occur, especially in older adults or those taking diuretics.
Which SGLT2 inhibitor was approved first?
Canagliflozin (Invokana) was the first SGLT2 inhibitor approved by the FDA, in March 2013. Dapagliflozin (Farxiga) followed in January 2014, and empagliflozin (Jardiance) in August 2014.
Are these drugs safe for older adults with dementia?
SGLT2 inhibitors can be used in older adults, but require careful monitoring. Risks of dehydration and low blood pressure are higher in this population, and a person with cognitive impairment may not recognize or communicate symptoms like dizziness or excessive thirst. Caregivers should ensure adequate fluid intake and watch for signs of urinary infections. The prescribing physician should weigh the cardiovascular and renal benefits against these practical challenges.
